There are 487 resources available
1537O - Value of immune checkpoint blockade (ICB) in microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC)
Presenter: Benjamin Geisler
Session: Proffered paper session: Policy and preventive strategies
Resources:
Abstract
Slides
Webcast
Conclusions
Presenter: Ron Mathijssen
Session: Current advances in clinical pharmacology within oncology, and its relevance for daily practice
Resources:
Slides
Webcast
608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)
Presenter: Wungki Park
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA25 - Randomized phase III trial of ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316)
Presenter: Stefan Kasper-Virchow
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
To operate or not operate: Personalised surgical approaches in the curative setting
Presenter: Guillaume Piessen
Session: Personalisation of surgical and systemic approaches in 2024: Optimising cure and quality of life in gastroesophageal cancer
Resources:
Slides
Webcast
502O - Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: Preliminary results of FFCD 1703 POCHI trial
Presenter: David Tougeron
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
Personalised systemic approaches to improve survivorship and cure
Presenter: Yelena Janjigian
Session: Personalisation of surgical and systemic approaches in 2024: Optimising cure and quality of life in gastroesophageal cancer
Resources:
Slides
Webcast
505O - Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
Presenter: Salvatore Siena
Session: Proffered paper session 2: GI tumours, lower
Resources:
Abstract
Slides
Webcast
How does surgery with curative intent impact quality of life?
Presenter: Jessie Elliott
Session: Personalisation of surgical and systemic approaches in 2024: Optimising cure and quality of life in gastroesophageal cancer
Resources:
Slides
Webcast
Invited Discussant 608O and LBA27
Presenter: Alexander Drilon
Session: Proffered paper session 2: Developmental therapeutics
Resources:
Slides
Webcast